Working on getting a bibliography of sorts for psychedelic ethics/philosophy papers together - sharing in case it comes in useful for anyone else!
Ongoing project & please feel free to let me know if I've missed something 🌿
katcheung.com/psychedelic-et…
In particular, many websites advertised possible medical and non-medical benefits of psilocybin services, raising questions about how online advertising, especially related to medical applications, may shape public expectations of psilocybin services.
We analyzed claims made in service centers' websites, and found substantial variation in how centers described psilocybin's benefits, risks, mechanisms, evidence base, and legal status.
With early data from the Oregon Health Authority showing that clients report seeking out psilocybin services in Oregon for a wide range of motivations, one question is how service centers are representing their services to the public.
This is an unusual & interesting survey in this space, and I invite you to take it.
The idea emerged at a @psychedelethics meeting at Oxford when the group realized we don't have data on what groups in the field think should received more funding/attention. Share your ideas!
🍄 @JHPsychedelics PSYCHEDELIC STAKEHOLDER SURVEY 🔬
There are more promising psychedelic research projects than there is funding. What should take priority?
Our new survey is open to anyone with a personal or professional interest in psychedelic science
[link below]
🍄 @JHPsychedelics PSYCHEDELIC STAKEHOLDER SURVEY 🔬
There are more promising psychedelic research projects than there is funding. What should take priority?
Our new survey is open to anyone with a personal or professional interest in psychedelic science
[link below]
"Safety in an Evolving Psychedelic Landscape: Knowledge and Use of Psilocybin Safety Strategies, Resources, and Support in a Naturalistic Oregon Sample"
sciencedirect.com/science/ar…
‼️ New paper! MDMA "blue Mondays" & "suicide Tuesdays" are familiar phrases in recreational MDMA culture, describing low points in the days post-use. But do these aftereffects actually exist? Current research shows conflicting results. Thread👇
doi.org/10.1007/s12152-026-0…
Beyond excited to announce this piece just published in @NeuroethicsJ!
During my research year at @JHPsychedelics, I had the privilege to co-facilitate prep, dosing and integration sessions for a number of participants in one of the psilocybin trials
"Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network"
frontiersin.org/journals/psy…
New paper in JME Practical Bioethics: Katherine Cheung @Katherine_Chg, Edward Jacobs @eddietalksdrugs, and David Yaden @ExistWell review the ethics of psychedelic clinical trials and flag key concerns to resolve as psychedelics move toward real-world care.
jmepb.bmj.com/content/2/4/e0…
Have you received psychedelic therapy through a legal pathway in Canada? 🇨🇦
We’re recruiting for a study in collaboration with the University of Ottawa @uOttawa.
Share your experience in a 15–25 min survey:
redcap.link/pace-ca#PsychedelicResearch#LivedExperience
A comprehensive review of bioethical progress and need for further work on psychedelic research and potential clinical applications across screening, informed consent, dosing, follow-up, & more. Work led by @Katherine_Chg w/ @eddietalksdrugs and me. Check out the thread and link:
A growing body of bioethical work has examined ethical issues related to the use of psychedelics in clinical research. With @eddietalksdrugs and @ExistWell, we try to take stock in our state-of-the-field review, published in JME Practical Bioethics.
While we have focused our review on the ethical challenges relevant to clinical trials, many of the considerations we discuss will remain relevant as psychedelics move towards clinical applications.